Latest Commercial Agreements News

Vanadium Resources has secured an oversubscribed A$1.0 million placement to advance studies, site work, offtake discussions and project financing for its planned V-Iron Plant in South Africa. The raise gives VR8 fresh development capital, but the project still depends on a scoping study, binding commercial agreements and a much larger funding package.

Emyria has secured a limited in-person speaking position at a US FDA hearing examining how psychedelic medicines could be delivered safely and at scale. The appearance gives the ASX-listed company a regulatory platform, but does not represent FDA approval, funding or a commercial agreement.

Optiscan Imaging has reached an 84-case milestone in its live digital pathology study with Australian Clinical Labs, testing the InForm platform across a broad range of tissue types and disease settings. The data may support future regulatory submissions and commercial discussions, but the announcement does not disclose diagnostic accuracy metrics or regulatory approval.

KTEK Aerosystems has secured a US$172,500 turnkey contract to design, tool and manufacture two composite prototypes for Israel-based Vestal Technology. The work adds a new customer, but any production beyond the prototypes remains uncertain.

Iondrive Limited’s updated evaluation of its IONSolv™ technology projects a US$243 million post-tax NPV and US$62 million annual EBITDA for a single rare earth recovery module in the US, driven by high feedstock grade assumptions and independently validated recoveries.

Tivan Limited’s Stage Two drilling at the Sandover Fluorite Project delivers broad, high-grade fluorite intersections up to 74.3% CaF2, validating exploration models and setting the stage for a maiden resource estimate.

Streamplay Studio Limited surged past $13 million in revenue for FY26, driven by a full year of Noodlecake Studios' contribution, while trimming its net loss by 15%.

Provaris Energy reported a $4.045 million loss for FY2026 as it progressed proprietary hydrogen and liquid CO₂ storage technologies, expanded strategic partnerships, and boosted cash reserves through multiple placements.

First Graphene lifted revenue by 15% to $537,594 for FY26 while narrowing its net loss slightly to $5.4 million. Key acquisitions and a landmark China cement distribution MOU set the stage for commercial expansion.

4DMedical’s CT:VQ™ lung imaging technology secured FDA clearance and CMS reimbursement, driving rapid adoption in top US medical centres and expanding its addressable market to $3 billion with new clinical programs and European contracts.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Nine Entertainment Co. Holdings Limited posted a $511 million statutory net profit for FY26, driven by significant portfolio restructuring and growth in digital and outdoor advertising, while advancing AI licensing partnerships.